Exagen
XGN
57 hedge funds and large institutions have $37M invested in Exagen in 2026 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 24 reducing their positions, and 11 closing their positions.
27% more capital invested
Capital invested by funds: $29M → $37M (+$7.95M)
7% less funds holding
Funds holding: 61 → 57 (-4)
7.32% less ownership
Funds ownership: 40.21% → 32.9% (-7.3%)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
38% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLPIM
F.L. Putnam Investment Management
Lynnfield,
Massachusetts
|
+$1.09M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.05M |
| 3 |
First Eagle Investment Management
New York
|
+$684K |
| 4 |
FCM
FourWorld Capital Management
New York
|
+$590K |
| 5 |
MBAM
Mink Brook Asset Management
West Palm Beach,
Florida
|
+$403K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.39M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.43M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$816K |
| 4 |
RI
RTW Investments
New York
|
-$754K |
| 5 |
Squarepoint
New York
|
-$677K |
XGN Hedge Fund Activity: Q2 2026 in Review
57 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q2 2026, worth a combined $37M — up 27% from $29M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of XGN and 8 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 15 added.
The largest buyer was F.L. Putnam Investment Management, opening a new position worth an estimated $1.09M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $2.39M sold.
- 57 institutional investors held Exagen (XGN) as of Q2 2026, down from 61 in Q1 2026.
- Funds reported $37M of Exagen stock for Q2 2026, up 27% quarter-over-quarter.
- 8 funds opened new Exagen positions in Q2 2026 and 11 closed out, a net change of -3 holders.
- The largest Exagen buyer in Q2 2026 was F.L. Putnam Investment Management, an estimated $1.09M added.
- The largest Exagen seller in Q2 2026 was Balyasny Asset Management, an estimated $2.39M sold.
Based on aggregated 13F filings for Q2 2026.